~~<i id='0019C24FA4'><strike id='0019C24FA4'><tt id='0019C24FA4'><pre id='0019C24FA4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

explore

author：knowledge 2025-09-27 23:32:43 - browse：2644

An illustration of red blood cells — Adobe

As a boy growing up with hemophilia A, Noah Frederick reserved the end of his annual checkups to talk about new technologies. His doctor walked through various experimental approaches for the bleeding disorder and, invariably, gene therapy. It was coming, he always said, in your lifetime.

Last year, it finally arrived. But Frederick, now a 23-year-old software engineer, isn’t sure he’ll get it. He wants to be part of the sci-fi future gene therapy has always represented, but a recent doctor’s visit left him uncertain.

“I’m on the fence,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

entertainment

hotspot

knowledge

AlexHogan/STATWASHINGTON—Anewtroveofinternalemailsandotherdocumentsfromthee-cigarettemakerJuulreveal

WSS

Study gives hint on South Asians’ higher risk of cardiovascular disease

All of Us, NIH's precision medicine initiative, gets a big boost

ACIP vaccine advisory panel sees its vacancies filled

Explaining an after

How to convince healthy people to buy insurance

Sarepta Duchenne therapy fails to meet primary endpoint in trial

entertainment

explore

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

Tome Biosciences co

Medicare proposal to cover medical devices draws a mixed reaction

Congress considering partial increase for doctor pay in Medicare

The cancer drug shortage isn’t new — and neither are the solutions

Eli Lilly reports tirzepatide MASH success during Q4 earnings

DIEP, the 'gold standard' of breast reconstruction, is under threat

Coloradans with cystic fibrosis could lose access to Trikafta

Hepatitis C has a cure — but many Americans still lack access to it

Live blog: Hearing on CRISPR

entertainment

Brain injuries and the importance of a second opinion

After Sarepta trial failure, Duchenne families brace for more debate

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Infant mortality in U.S. rose last year for first time in decades: CDC

Juul documents reveal insider tactics on political lobbying

Bill would allow buprenorphine prescription for addiction via telehealth

hotspot

hotspot

hotspot

knowledge